Associated Papers
Using Portuguese BRCA pathogenic variation as a model to study the impact of human admixture on human health.
Andaluz S et al.
Bmc Genomics, 2024
38671360 (PubMed )
Supplement: 12864_2024_10311_MOESM6_ESM.xlsx › BRCA1
Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
Magliacane G et al.
Cancers, 2022
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy.
Figlioli G et al.
Cancers, 2021
33573335 (PubMed )
Supplement: cancers-13-00532-s001.zip › cancers-1044931-supplementary.xlsx › Suppl_Table
The germline mutational landscape of BRCA1 and BRCA2 in Brazil.
Palmero EI et al.
Scientific Reports, 2018
A novel crosstalk between BRCA1 and sirtuin 1 in ovarian cancer.
Li D et al.
Scientific Reports, 2014
25323003 (PubMed )
Supplement: srep06666-s1.pdf
Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer.
Fang YY et al.
Bmc Cancer, 2014
24629067 (PubMed )
Supplement: 1471-2407-14-188-S1.pdf
BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
Li D et al.
Cell Cycle (georgetown, Tex.), 2014
25486197 (PubMed )
Supplement: supplement_1.pdf
Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer.
Li D et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2013
24321281 (PubMed )
Supplement: 1756-9966-32-102-S1.pdf
Regulation of angiotensin II type 1 receptor expression in ovarian cancer: a potential role for BRCA1.
Bi FF et al.
Journal of Ovarian Research, 2013
24321324 (PubMed )
Supplement: 1757-2215-6-89-S1.pdf
Select a paper to view details